MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6288
+0.0364
+6.14%
After Hours: 0.6102 -0.0186 -2.96% 18:52 01/28 EST
OPEN
0.6000
PREV CLOSE
0.5924
HIGH
0.6400
LOW
0.5710
VOLUME
3.48M
TURNOVER
--
52 WEEK HIGH
21.60
52 WEEK LOW
0.2350
MARKET CAP
7.68M
P/E (TTM)
-0.1042
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OCGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

OCGN News

  • Comcast: 5%+ Correction Post Q4 Results Not Justified: Reiterate Buy
  • Seeking Alpha - Article.4d ago
  • Comcast -1.2% as UBS sees investments weighing growth
  • Seeking Alpha - Article.4d ago
  • Here are the biggest analyst calls of the day: Alphabet, Apple, PayPal, Intel & more
  • CNBC.com.4d ago
  • ClearBridge Multi Cap Growth Strategy Portfolio Manager Commentary Q4 2019
  • Seeking Alpha - Article.4d ago

More

Industry

Pharmaceuticals
+0.48%
Pharmaceuticals & Medical Research
+0.58%

Hot Stocks

Name
Price
%Change

About OCGN

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).
More

Webull offers Ocugen Inc (OCGN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.